Moderna Inc. (MRNA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, MRNA scores 60 out of 100, graded C- and labeled "Roarable Hold — Cautious Neutral." The five pillars are:

• Fundamental Cash Engine: 10 / 20. Per the Roarable RQD rating, ROIC is -34.1% and FCF yield is -2.32%. This is the weakest pillar relative to its weight, indicating the business is not currently generating cash returns on invested capital.
• Whale 13F Flow: 20 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning at the maximum score. Institutional interest is a notable positive, though the source data does not itemize the underlying holdings.
• Insider Conviction: 5 / 20. Per the Roarable RQD rating, SEC Form 4 and Congressional PTR cluster flow scores low, a weak signal from insider activity.
• Macro Regime Fit: 11 / 20. Per the Roarable RQD rating, beta is 1.1 with moderate sector sensitivity, so the stock is expected to move somewhat more than the market.
• Forensic Balance Sheet: 14 / 20. Per the Roarable RQD rating, Altman Z is 15.07, Piotroski F is 5/9, and Debt/Equity is 0.07. The balance sheet is comparatively sound relative to the earnings profile.

Investor implications: the upside case rests mainly on institutional conviction and the balance sheet cushion, which give the company runway. The valuation tradeoff is that per the market data, EPS (TTM) is -7.07 and the operating margin is -60%, so the current price of 222.76 is being supported by forward expectations (forward P/E of 32) rather than trailing cash generation. Investors should weigh the gap between a strong balance sheet and negative operating cash flow as the central tension in this rating.

Moderna Inc. (MRNA) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry, per the company profile. Per the company profile, the market capitalization is $88.9B. The source data does not describe specific products, customer segments, or revenue model beyond the sector and industry classification, and the profile does not detail how the company earns revenue. Per the SEC financials, reported revenue declined from $6848.0M in FY 2023 to $1944.0M in FY 2025.

Per the SEC financials, every reported period shows operating and net losses, and free cash flow was negative in each year. Per the market data, the gross margin is 55.3%, while operating and net margins are both -60%, and ROIC is -34.1%. Per the Roarable RQD rating, the Altman Z-Score is 15.07 and the Piotroski F-Score is 5/9. Per the Roarable RQD rating, Debt/Equity is 0.07, and per the SEC financials, debt fell from $11445.8M in FY 2023 to $590.0M in FY 2025 while cash rose to $2595.0M.

Per the news wire, the headlines are dominated by a planned national cancer vaccine effort, which one report describes as a four-year high for the stock. Several reports cover a sharp decline tied to cancer-vaccine data shared on social media, and an analyst fair value revision on the cancer vaccine. One report attributes a sharp rally to a cancer vaccine breakthrough, and another notes a gain of over $4B in a week. Per the news wire tags, the two most recent items are flagged as CATALYST with GREEN signals, while the rest are MARKET WIRE with YELLOW signals. Risk watch items per the news wire include the volatility around clinical data disclosure. Per the Butterfly Supply-Chain Graph, the supply chain is NONE and no proprietary signals are present.

Per the Butterfly Supply-Chain Graph, supply chain is NONE, and there are no butterfly links or proprietary signals. Not available in source data for upstream or downstream dependencies. Based on the sector classification alone, a prospective investor should watch how cancer-vaccine news flows through the broader biotechnology group, since the news wire shows the stock reacting sharply to clinical-data headlines. The source data does not establish specific 2nd-order bottlenecks.

• What is the trailing P/E and EV/EBITDA, which the source data lists as unavailable, and how do they compare with peers?
• What is the revenue mix and the product or pipeline driving the cancer-vaccine catalyst, and what is its timing?
• Why does free cash flow remain negative despite a debt reduction from $11445.8M to $590.0M, and what is the cash burn runway?
• Which institutions drive the 20/20 whale flow score, and are the holders accumulating or distributing?
• What is the analyst consensus and price target range, which the source data does not provide?